
Phase 3 Data Support ENTYVIO® (vedolizumab) for Pediatric Moderate to Severe Ulcerative Colitis
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis Takeda today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility…












